GSK Trelegy Ellipta: Forecasting Its Evolution

GSK Trelegy Ellipta: Forecasting Its Evolution

February 08, 2018

Developing triple therapies for COPD has been fashionable for a while. GSK, AZ, BI, Chiesi are at it. I had the chance in the last few years to review the field and publish articles on the topic:

Forecasting the success of triple therapy is difficult. Clinical efficacy is not enough, products have to be seen within their commercial context: payor, patients, practitioners. Financial analysts provide the best reviews because they give a context and hard financials against clinical studies.

Seeking Alpha published an analysis of the potential of Trelegy worth reading: Understanding GlaxoSmithKline's Trelegy Ellipta (2018):

Trelegy was approved for use in the US on 18 September 2017 for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Trelegy is made of fluticasone furoate 100 mcg, umeclidinium 62.5 mg and vilanterol 25 mcg: the ICS component places it at odds with BI view on the use of ICS.

Current Trelegy sales forecast stand at $780m per annum. A fantasy figure for now that keeps on fluctuating. In 4Q17 recorded sales were $2m. Breo and Anoro Ellipta launches have so far been disappointing.

Read the analysis to get a flavour of where Trelegy and triple therapies might be going next!

Philippe @

About Aedestra ( Aedestra is an inhaled product development company. We develop inhaled dosage forms: DPI, pMDI, Nasal, Nebule and SoftMist: Generics in particular. Aedestra can help you develop the right product in the right way by providing strategic and technical expertise. Get in touch now to expand and develop your inhaled portfolio: